PortfoliosLab logoPortfoliosLab logo
MDGL vs. VKTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MDGL vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Madrigal Pharmaceuticals, Inc. (MDGL) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both stocks are quite close, with MDGL having a -16.17% return and VKTX slightly lower at -16.63%. Over the past 10 years, MDGL has outperformed VKTX with an annualized return of 43.76%, while VKTX has yielded a comparatively lower 35.08% annualized return.


MDGL

1D
7.79%
1M
-5.88%
YTD
-16.17%
6M
-15.82%
1Y
71.64%
3Y*
23.37%
5Y*
37.02%
10Y*
43.76%

VKTX

1D
0.14%
1M
-7.65%
YTD
-16.63%
6M
-17.17%
1Y
10.22%
3Y*
9.60%
5Y*
41.01%
10Y*
35.08%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MDGL vs. VKTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MDGL
Madrigal Pharmaceuticals, Inc.
-16.17%88.72%33.36%-20.28%242.52%-23.77%22.02%-19.17%22.80%516.04%
VKTX
Viking Therapeutics, Inc.
-16.63%-12.57%116.23%97.98%104.35%-18.29%-29.80%4.84%88.42%241.18%

Correlation

The correlation between MDGL and VKTX is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.39

Correlation (3Y)
Calculated over the trailing 3-year period

0.38

Correlation (5Y)
Calculated over the trailing 5-year period

0.46

Correlation (10Y)
Calculated over the trailing 10-year period

0.42

Correlation (All Time)
Calculated using the full available price history since Apr 30, 2015

0.38

Fundamentals

Market Cap

MDGL:

$14.17B

VKTX:

$3.39B

EPS

MDGL:

-$12.87

VKTX:

-$4.16

PB Ratio

MDGL:

26.08

VKTX:

6.75

Total Revenue (TTM)

MDGL:

$1.13B

VKTX:

$0.00

Gross Profit (TTM)

MDGL:

$1.05B

VKTX:

-$208.00K

EBITDA (TTM)

MDGL:

-$287.63M

VKTX:

-$501.77M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MDGL vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDGL
MDGL Risk / Return Rank: 7979
Overall Rank
MDGL Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
MDGL Sortino Ratio Rank: 8181
Sortino Ratio Rank
MDGL Omega Ratio Rank: 7878
Omega Ratio Rank
MDGL Calmar Ratio Rank: 7878
Calmar Ratio Rank
MDGL Martin Ratio Rank: 7676
Martin Ratio Rank

VKTX
VKTX Risk / Return Rank: 4747
Overall Rank
VKTX Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 4747
Sortino Ratio Rank
VKTX Omega Ratio Rank: 5050
Omega Ratio Rank
VKTX Calmar Ratio Rank: 4646
Calmar Ratio Rank
VKTX Martin Ratio Rank: 4646
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDGL vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MDGLVKTXDifference

Sharpe ratio

Return per unit of total volatility

1.57

0.14

+1.43

Sortino ratio

Return per unit of downside risk

2.44

0.72

+1.72

Omega ratio

Gain probability vs. loss probability

1.29

1.11

+0.18

Calmar ratio

Return relative to maximum drawdown

2.45

0.23

+2.23

Martin ratio

Return relative to average drawdown

5.56

0.46

+5.10

MDGL vs. VKTX - Sharpe Ratio Comparison

The current MDGL Sharpe Ratio is 1.57, which is higher than the VKTX Sharpe Ratio of 0.14. The chart below compares the historical Sharpe Ratios of MDGL and VKTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


MDGLVKTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.57

0.14

+1.43

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.28

0.41

-0.13

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.37

0.36

+0.01

Sharpe Ratio (All Time)

Calculated using the full available price history

0.02

0.11

-0.09

Drawdowns

MDGL vs. VKTX - Drawdown Comparison

The maximum MDGL drawdown since its inception was -98.40%, which is greater than VKTX's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for MDGL and VKTX.


Loading charts...

Drawdown Indicators


MDGLVKTXDifference

Max Drawdown

Largest peak-to-trough decline

-98.40%

-90.41%

-7.99%

Max Drawdown (1Y)

Largest decline over 1 year

-29.36%

-45.14%

+15.78%

Max Drawdown (3Y)

Largest decline over 3 years

-56.45%

-78.86%

+22.41%

Max Drawdown (5Y)

Largest decline over 5 years

-61.41%

-78.86%

+17.45%

Max Drawdown (10Y)

Largest decline over 10 years

-82.19%

-89.26%

+7.07%

Current Drawdown

Current decline from peak

-19.02%

-68.96%

+49.94%

Average Drawdown

Average peak-to-trough decline

-58.56%

-60.01%

+1.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.94%

22.29%

-9.35%

Volatility

MDGL vs. VKTX - Volatility Comparison

Madrigal Pharmaceuticals, Inc. (MDGL) has a higher volatility of 16.33% compared to Viking Therapeutics, Inc. (VKTX) at 13.65%. This indicates that MDGL's price experiences larger fluctuations and is considered to be riskier than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MDGLVKTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.33%

13.65%

+2.68%

Volatility (6M)

Calculated over the trailing 6-month period

31.56%

41.31%

-9.75%

Volatility (1Y)

Calculated over the trailing 1-year period

46.14%

73.85%

-27.71%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

133.42%

101.62%

+31.80%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

117.52%

97.09%

+20.43%

Dividends

MDGL vs. VKTX - Dividend Comparison

Neither MDGL nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MDGL vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
311.34M
0
(MDGL) Total Revenue
(VKTX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MDGL and VKTX have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MDGL has higher volatility (16.33%) compared to VKTX (13.65%). In terms of maximum drawdown, MDGL dropped -98.40% vs VKTX's -90.41%.

MDGL currently has the higher Sharpe Ratio (1.57 vs 0.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MDGL and VKTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer